Review
Chemistry, Multidisciplinary
Bicai Tang, Wenjuan Ma, Yunfeng Lin
Summary: Studies have shown the potential of nanomaterials in inhibiting pathological angiogenesis, providing new options for cancer treatment. Compared to traditional anti-angiogenic agents, nanomaterials have better targeting capabilities and therapeutic outcomes, reducing side effects.
JOURNAL OF CONTROLLED RELEASE
(2023)
Review
Oncology
Lars M. Schiffmann, Christiane J. Bruns, Thomas Schmidt
Summary: Anti-angiogenic therapies have not met expectations in clinical trials, as patients develop resistance. Understanding resistance mechanisms is crucial for improving treatment efficacy.
FRONTIERS IN ONCOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Filipa Lopes-Coelho, Filipa Martins, Sofia A. Pereira, Jacinta Serpa
Summary: Anti-angiogenic therapy aims to fight cancer by disrupting the nutrient and oxygen supply to tumor cells, mainly by targeting vascular endothelial growth factor (VEGF). While some drugs in this category can enhance immune therapy, they often fall short in terms of efficacy. Researchers believe that targeting alternative angiogenic pathways in combination could be a promising solution.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Oncology
Zi-Wu Ye, Zi-Li Yu, Gang Chen, Jun Jia
Summary: Tumor angiogenesis is crucial for cancer development, but its inhibition through anti-angiogenic therapy (AAT) is often limited due to resistance. Recent studies suggest that tumor cell-derived extracellular vesicles (T-EVs) play a major role in the development of resistance to AAT by promoting tumor angiogenesis. Furthermore, the role of EVs from non-tumor cells in angiogenesis and their involvement in resistance mechanisms are still not fully understood. This review provides a comprehensive overview of the role of EVs in tumor angiogenesis, resistance to AAT, and proposed strategies for improving AAT efficacy by inhibiting T-EVs.
Review
Pharmacology & Pharmacy
Nehad M. Ayoub, Sara K. Jaradat, Kamal M. Al-Shami, Amer E. Alkhalifa
Summary: Angiogenesis plays a vital role in the growth and spread of solid cancers, but breast cancer has shown poor response to anti-angiogenic drugs. Assessing the angiogenic signaling mechanisms in breast cancer, exploring new drug targets, and improving treatment outcomes through vascular normalization and nanotechnology are important areas of research.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Oncology
Changyu Yao, Shilun Wu, Jian Kong, Yiwen Sun, Yannan Bai, Ruhang Zhu, Zhuxin Li, Wenbing Sun, Lemin Zheng
Summary: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths, and angiogenesis plays a crucial role in its development and progression. Current anti-angiogenic therapies targeting VEGFR and PDGFR have limited survival benefits, highlighting the need for new therapeutic targets. Recent studies have uncovered the molecular mechanisms of angiogenesis in HCC, involving pro-angiogenic factors, the tumor microenvironment, and cancer stem cells. This review summarizes these mechanisms and discusses potential novel therapeutic targets for more effective anti-angiogenic treatment of HCC.
CANCER BIOLOGY & MEDICINE
(2023)
Review
Oncology
Ashley B. B. Zhang, Khashayar Mozaffari, Brian Aguirre, Victor Li, Rohan Kubba, Nilay C. Desai, Darren Wei, Isaac Yang, Madhuri Wadehra
Summary: Glioblastoma, the most common malignant primary brain tumor, has a poor prognosis despite advancements in treatment. Angiogenesis, particularly involving vascular endothelial growth factor-A (VEGF-A), plays a critical role in the growth and invasion of glioblastoma cells. Bevacizumab, a medication targeting VEGF-A, has been approved for recurrent glioblastoma but has not significantly improved survival. Other agents with similar mechanisms of action have also shown unfavorable results. This review explores the current state and future potential of anti-angiogenesis therapeutic agents.
Review
Oncology
Mingshu Xiao, Yueli Shi, Sujing Jiang, Mengqing Cao, Weiyu Chen, Yun Xu, Zhiyong Xu, Kai Wang
Summary: Anti-angiogenesis therapy and immunotherapy are important strategies for tumor treatment. Nanomedicine has unique advantages in anti-angiogenesis therapy, such as targeted delivery and photothermal effects. This review provides a comprehensive overview on the use of nanomaterials in anti-angiogenesis therapy, focusing on the immunosuppressive effects of abnormal tumor vessels, targeting strategies of anti-angiogenesis nanomedicines, and the synergistic effects and molecular mechanisms when combined with immunotherapy.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, Research & Experimental
Sebastian A. Wohlfeil, Verena Haefele, Bianca Dietsch, Celine Weller, Carsten Sticht, Anna Sophia Jauch, Manuel Winkler, Christian David Schmid, Anna Lena Irkens, Ana Olsavszky, Kai Schledzewski, Philipp-Sebastian Reiners-Koch, Sergij Goerdt, Cyrill Geraud
Summary: This study investigates the efficiency and vascularization patterns of different mouse melanoma cell lines in liver metastasis. The highly and moderately metastatic melanomas are associated with gene clusters involved in cell migration and angiogenesis. Sorafenib shows a strong inhibitory effect on vascularization in liver metastasis of melanoma.
JOURNAL OF TRANSLATIONAL MEDICINE
(2022)
Review
Oncology
Zhengyang Yang, Wei Deng, Xiao Zhang, Yongbo An, Yishan Liu, Hongwei Yao, Zhongtao Zhang
Summary: Digestive tumours are a common type of malignancy that have led to the highest number of tumour-related deaths. Abnormal angiogenesis, the formation of new blood vessels, plays a crucial role in the growth, progression, and metastasis of these tumours. Traditional anti-angiogenic therapies have limitations and resistance issues, but nanotechnology-based therapies using nanoparticles show promise in targeted drug delivery and increased drug bioavailability. This review outlines the mechanisms of angiogenesis, the effects of nanoparticles on angiogenesis, and their biomedical applications in digestive tumours.
FRONTIERS IN ONCOLOGY
(2022)
Review
Medicine, Research & Experimental
Xuan Yan, Zhangyan Zhao, Haicheng Tang
Summary: Lung cancer, a high incidence and mortality malignant tumor in China, is a major cause of death and a significant public health problem. Anti-angiogenesis has become a crucial approach to inhibit tumor development by rebalancing pro- and anti-angiogenic factors. This article reviews the mechanism of blood vessel formation in tumor tissues, the action mechanism of different anti-angiogenic drugs, the combination therapy of anti-angiogenic drugs with other anti-tumor drugs, and the mechanism of anti-angiogenic drug resistance.
CLINICAL AND EXPERIMENTAL MEDICINE
(2023)
Article
Biotechnology & Applied Microbiology
Claudia Kuehlbach, Sabine Hensler, Margareta M. Mueller
Summary: Tumor cells modify tissue homeostasis by secreting cytokines, activating the tumor microenvironment and promoting vascularization. A 3D organotypic model with microtumor spheroids and various cell types has been established to study tumor-stroma interactions. This model is suitable for testing novel anticancer therapeutics targeting both the tumor and the vascular compartment.
BIOENGINEERING-BASEL
(2021)
Review
Food Science & Technology
Pradipta Jana, Krishnendu Acharya
Summary: Anti-angiogenic therapy is a targeted prognosis for treating advanced stage cancer. Naturally obtained products from mushrooms have shown potential in inhibiting angiogenesis and modulating immune response.
FOOD REVIEWS INTERNATIONAL
(2022)
Review
Immunology
Jingyao Tu, Hang Liang, Chunya Li, Yongbiao Huang, Ziqi Wang, Xinyi Chen, Xianglin Yuan
Summary: Tumor immunotherapy has become a focus of research and treatment due to its effectiveness and fewer side effects compared to traditional treatments. However, the abnormal angiogenesis state of tumors can affect the efficacy of immunotherapy. The application of anti-angiogenesis drugs to normalize tumor vessels has shown promise in improving the effectiveness of immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Behnaz Lahooti, Sagun Poudel, Constantinos M. Mikelis, George Mattheolabakis
Summary: Angiogenesis is crucial for tumor growth and metastasis, with miRNAs playing a role in tumor progression. Current anti-angiogenic approaches provide clinical benefit but come with significant side effects.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Julia Femel, Luuk van Hooren, Melanie Herre, Jessica Cedervall, Falk Saupe, Elisabeth J. M. Huijbers, Danielle R. J. Verboogen, Matthias Reichel, Victor L. Thijssen, Arjan W. Griffioen, Lars Hellman, Anna Dimberg, Anna-Karin Olsson
Summary: Galectin-1 (Gal1) is a glycan-binding protein that promotes tumor progression through various mechanisms. Vaccination against Gal1 can generate high anti-Gal1 antibody levels and significantly impairs the growth of Gal1-expressing melanomas in mice. This is associated with improved tumor vasculature perfusion and increased infiltration of macrophages and cytotoxic T cells. Gal1 vaccination is a promising approach to enhance immunotherapeutic strategies for cancer therapy.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Review
Immunology
Elisabeth J. M. Huijbers, Kabir A. Khan, Robert S. Kerbel, Arjan W. Griffioen
Summary: Tumors can escape immunity by inducing a state of unresponsiveness in tumor vasculature, leading to compromised immune responses. By mimicking embryonic mechanisms through angiogenesis, tumors enforce immune privileged conditions to ensure uninterrupted growth.
SCIENCE IMMUNOLOGY
(2022)
Correction
Oncology
Julia Femel, Luuk van Hooren, Melanie Herre, Jessica Cedervall, Falk Saupe, Elisabeth J. M. Huijbers, Danielle R. J. Verboogen, Matthias Reichel, Victor L. Thijssen, Arjan W. Griffioen, Lars Hellman, Anna Dimberg, Anna-Karin Olsson
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Multidisciplinary Sciences
Judy R. van Beijnum, Elisabeth J. M. Huijbers, Karlijn van Loon, Athanasios Blanas, Parvin Akbari, Arno Roos, Tse J. Wong, Stepan S. Denisov, Tilman M. Hackeng, Connie R. Jimenez, Patrycja Nowak-Sliwinska, Arjan W. Griffioen
Summary: Anti-angiogenic cancer therapies have immune-stimulatory properties. This study found that tumor endothelial cells overexpress and secrete the protein vimentin, which promotes angiogenesis and inhibits leukocyte-endothelial interactions. Targeting extracellular vimentin shows inhibition of angiogenesis and tumor growth, and induces a pro-inflammatory condition in the tumor.
NATURE COMMUNICATIONS
(2022)
Article
Oncology
Karlijn van Loon, Elisabeth J. M. Huijbers, Jan David de Haan, Arjan W. Griffioen
Summary: Vaccination using the biodegradable adjuvant Montanide ISA 720, supplemented with CpG, shows potential for effective immunization against extracellular vimentin and tumor growth inhibition in preclinical studies. This study highlights the importance of the adjuvant used in vaccination efficacy, suggesting that Montanide ISA 720 could be a promising option for clinical trials in cancer patients.
Editorial Material
Biochemistry & Molecular Biology
Arjan W. Griffioen, Patrycja Nowak-Sliwinska
Summary: Research on cell death mechanisms is of great significance for biology, pathology, and therapeutic intervention. In recent years, there has been a steady increase in scientific reports and impact of this literature on understanding the different mechanisms of programmed cell death, with the emergence of new concepts.
Article
Chemistry, Medicinal
I. H. Bartelink, E. A. van de Stadt, A. F. Leeuwerik, V. L. J. L. Thijssen, J. R. Hupsel, J. F. van den Nieuwendijk, I Bahce, M. Yaqub, N. H. Hendrikse
Summary: The developed physiological pharmacokinetic (PBPK) models accurately predicted the image quality and contrast of EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer. These models provide the potential for predicting the image quality of new tracers in the future.
Article
Biochemistry & Molecular Biology
Lionel Mendes Dias, Mark J. de Keijzer, Daniel Ernst, Farangis Sharifi, Daniel J. de Klerk, Tony G. Kleijn, Emilie Desclos, Jakub A. Kochan, Lianne R. de Haan, Leonardo P. Franchi, Albert C. van Wijk, Enzo M. Scutigliani, Marcel H. Fens, Arjan D. Barendrecht, Jose E. B. Cavaco, Xuan Huang, Ying Xu, Weiwei Pan, Marjo J. den Broeder, Jan Bogerd, Rudiger W. Schulz, Kitty C. Castricum, Victor L. Thijssen, Shuqun Cheng, Baoyue Ding, Przemek M. Krawczyk, Michal Heger
Summary: The study developed a comprehensive tumor targeting and photosensitizer delivery platform. It was found that photodynamically active PSs effectively photosensitized cancer cells and non-cancerous cells without notable systemic toxicity. ZnPC and AlPC delivered by ITLs demonstrated strong tumor-killing capacity in human breast cancer xenografts.
JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY
(2022)
Article
Oncology
George M. Ramzy, Laura Boschung, Thibaud Koessler, Celine Delucinge-Vivier, Mylene Docquier, Thomas A. McKee, Laura Rubbia-Brandt, Patrycja Nowak-Sliwinska
Summary: In this study, we created colorectal cancer models in vitro to study how induced drug resistance can affect cell response and sensitivity to treatment. By exposing the cells to first-line treatments, we obtained resistance to chemotherapy and identified key genes involved. We also found that optimized drug combinations can overcome chemotherapy-induced resistance.
Article
Peripheral Vascular Disease
Patrycja Nowak-Sliwinska, Judy R. van Beijnum, Christian J. Griffioen, Zowi R. Huinen, Nadine Grima Sopesens, Ralph Schulz, Samir V. Jenkins, Ruud P. M. Dings, Floris H. Groenendijk, Elisabeth J. M. Huijbers, Victor L. J. L. Thijssen, Eric Jonasch, Florry A. Vyth-Dreese, Ekaterina S. Jordanova, Axel Bex, Rene Bernards, Tanja D. de Gruijl, Arjan W. Griffioen
Summary: This study aimed to investigate whether anti-angiogenic agents can overcome tumor endothelial cell anergy and provide pro-inflammatory conditions. The results showed that treatment with VEGF pathway-targeted drugs can overcome tumor endothelial cell anergy and promote an inflammatory state in renal cell carcinoma, leading to enhanced infiltration of various leukocyte subsets.
Article
Biochemistry & Molecular Biology
Dina Hany, Marloes Zoetemelk, Kaushik Bhattacharya, Patrycja Nowak-Sliwinska, Didier Picard
Summary: Breast cancer is a persistent threat to women worldwide, and current monotherapies often face issues of drug resistance and toxicity. By mining data and constructing a network, we identified two multidrug combinations with high therapeutic relevance for ER alpha positive/HER2-/PI3K alpha mutant subtype of breast cancer.
CELLULAR AND MOLECULAR LIFE SCIENCES
(2023)
Article
Oncology
George M. Ramzy, Maxim Norkin, Thibaud Koessler, Lionel Voirol, Mathieu Tihy, Dina Hany, Thomas McKee, Frederic Ris, Nicolas Buchs, Mylene Docquier, Christian Toso, Laura Rubbia-Brandt, Gaetan Bakalli, Stephane Guerrier, Joerg Huelsken, Patrycja Nowak-Sliwinska
Summary: This study proposes a new approach for designing personalized treatment for colorectal cancer patients by combining efficacy testing and mathematical modeling. The research identified four low-dose synergistic drug combinations that showed promising results in both primary and metastatic colorectal cancer models. This approach allows for the optimization of patient-tailored multi-drug combinations within a clinically relevant timeframe.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Diederik J. M. Engbersen, Judy R. van Beijnum, Arno Roos, Marit van Beelen, Jan David de Haan, Guy C. M. Grinwis, Jack A. Schalken, J. Alfred Witjes, Arjan W. Griffioen, Elisabeth J. M. Huijbers
Summary: This study investigated the safety and usefulness of treating dogs with spontaneous bladder cancer using the CVx1 vaccine. The vaccine targets a specific protein released by tumor blood vessels and was combined with the anti-inflammatory drug meloxicam. All dogs responded well to the treatment and developed an immune response against the tumor blood vessels. Survival was significantly increased with the CVx1 vaccine plus meloxicam compared to traditional chemotherapy. The results support the further development of the CVx1 vaccine for human patients.
Article
Oncology
Charlotte Stroes, Sandor Schokker, Mohammed Khurshed, Stephanie O. van der Woude, Ron A. A. Mathot, Marije Slingerland, Judith de Vos-Geelen, Massimo Zucchetti, Cristina Matteo, Erik van Dijk, Bauke Ylstra, Victor Thijssen, Sarah Derks, Tesfay Godefa, Willemieke Dijksterhuis, Gerben E. Breimer, Otto M. van Delden, Rob H. A. Verhoeven, Sybren L. Meijer, Maarten F. Bijlsma, Hanneke W. M. van Laarhoven
Summary: The study evaluated the tolerability and efficacy of regorafenib and paclitaxel combination therapy in patients with advanced esophagogastric cancer refractory to first-line treatment. The results showed promising potential of this combination therapy in improving patient survival rates, while identifying potential negative predictive biomarkers for treatment response.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2022)
